Dave (DAVE) had the highest return between December 27, 2023 and January 30, 2024 by a mid-cap US stock, returning 114.5%.
| ASSET | DATE | % RETURN |
|---|---|---|
Dave (DAVE) | 12/27/2023 - 1/30/2024 | 114.48% |
Vera Therapeutics (VERA) | 12/27/2023 - 1/30/2024 | 114.08% |
Trump Media & Technology (DJT) | 12/27/2023 - 1/30/2024 | 107.35% |
Sezzle (SEZL) | 12/27/2023 - 1/30/2024 | 101.24% |
Arcutis Biotherapeutics (ARQT) | 12/27/2023 - 1/30/2024 | 92.46% |
Immunome (IMNM) | 12/27/2023 - 1/30/2024 | 81.73% |
NewAmsterdam Pharma Company NV Ordinary Shares (NAMS) | 12/27/2023 - 1/30/2024 | 77.4% |
Praxis Precision Medicines (PRAX) | 12/27/2023 - 1/30/2024 | 72.15% |
Dyne Therapeutics (DYN) | 12/27/2023 - 1/30/2024 | 65.86% |
Edgewise Therapeutics (EWTX) | 12/27/2023 - 1/30/2024 | 64.1% |
Establishment Labs (ESTA) | 12/27/2023 - 1/30/2024 | 49.61% |
Spyre Therapeutics (SYRE) | 12/27/2023 - 1/30/2024 | 42.49% |
ZIM Integrated Shipping Services (ZIM) | 12/27/2023 - 1/30/2024 | 39.77% |
Oscar Health (OSCR) | 12/27/2023 - 1/30/2024 | 37.74% |
Tarsus Pharmaceuticals (TARS) | 12/27/2023 - 1/30/2024 | 36.36% |
Mineralys Therapeutics, Inc Common Stock (MLYS) | 12/27/2023 - 1/30/2024 | 31.2% |
Appfolio (APPF) | 12/27/2023 - 1/30/2024 | 27.93% |
Kemper (KMPR) | 12/27/2023 - 1/30/2024 | 26.32% |
CG Oncology, Inc Common stock (CGON) | 12/27/2023 - 1/30/2024 | 25.86% |
GeneDx (WGS) | 12/27/2023 - 1/30/2024 | 24.42% |
Merus (MRUS) | 12/27/2023 - 1/30/2024 | 24.24% |
Viking Therapeutics (VKTX) | 12/27/2023 - 1/30/2024 | 23.36% |
Sarepta Therapeutics (SRPT) | 12/27/2023 - 1/30/2024 | 23.14% |
Rumble (RUM) | 12/27/2023 - 1/30/2024 | 23.03% |
Ideaya Biosciences (IDYA) | 12/27/2023 - 1/30/2024 | 22.75% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
